Last updated: July 28, 2025
Introduction
European Patent EP2269603, titled “Method for delivering therapeutic agents”, was granted by the European Patent Office (EPO). As a critical component in the pharmaceutical innovation landscape, this patent’s scope, claims, and the broader patent environment surrounding it reveal valuable insights into its strategic importance and the competitive landscape in drug delivery technologies.
This analysis examines the patent’s scope, dissects its claims, and evaluates its position within the existing patent landscape, providing insights useful for stakeholders involved in pharmaceutical R&D, licensing, or strategic patent management.
Patent Overview and Technical Field
EP2269603 pertains to advanced drug delivery methods, specifically focusing on controlled release systems for therapeutic agents. It covers formulations and methods that enhance drug bioavailability, stability, and patient compliance, with applications spanning chronic disease management, targeted therapy, and personalized medicine.
The patent emphasizes multiparticulate systems, such as micro- and nanoparticles, capable of controlled and site-specific drug release, addressing limitations of conventional delivery methods like systemic side effects and variable pharmacokinetics.
Scope and Claims Analysis
Scope Summary
The patent’s scope is primarily defined by its claims concerning:
- Specific formulations combining active pharmaceutical ingredients (APIs) with particular carrier materials.
- Modulation of drug release profiles through tailored core/shell particle architectures.
- Methods of manufacturing these multiparticulate systems.
- Use of specific polymers and excipients to achieve targeted release.
This scope aims to provide broad protective coverage for controlled-release formulations that employ particular manufacturing techniques and carrier compositions, thereby creating a robust barrier against infringement by generics or competing innovations.
Claim Structure and Key Elements
Claim 1 - Independent Claim:
- Focus: A multiparticulate drug delivery system comprising an API encapsulated within a polymeric carrier, engineered to modulate release kinetics.
- Features: Includes specific parameters such as particle size ranges, polymer composition, and the method of manufacturing.
- Significance: Provides broad protection, encompassing various therapeutic agents and carrier materials that fit within the defined specifications.
Dependent Claims:
- Add further limitations, such as specific polymer types (e.g., biodegradable polyesters), pH-sensitive coatings, or manufacturing conditions (e.g., spray-drying, fluid-bed coating).
- Cover alternative embodiments with varying core-shell configurations, multiple APIs, or combined delivery systems.
Claim Interpretation:
The claims are constructed to be sufficiently broad to cover multiple drug classes and delivery scenarios, but also precise enough to distinguish from prior art by emphasizing particular combinations and methods.
Patent Landscape Context
Prior Art and Related Patents
This patent intersects with extensive prior art centered around controlled-release formulations, multiparticulate systems, and polymer-based encapsulation technologies. Notably:
- Controlled-release technologies: Previous patents have addressed various polymers such as ethylcellulose, poly(lactic-co-glycolic acid) (PLGA), and other biodegradable materials.
- Multiparticulate systems: Prior systems include microcapsules, pellets, and coated beads, with notable patents from the pharmaceutical industry such as US patents on multiparticulate formulations for improved bioavailability.
- Manufacturing techniques: Spray-drying, fluid-bed coating, and extrusion processes dominate the innovation landscape.
The patent fills technological gaps by combining specific manufacturing protocols with novel polymer compositions, providing an inventive step over existing solutions.
Landscape Trends and Patent Families
Over the past decade, patent filings reveal a trend toward personalized, targeted drug delivery systems that improve therapeutic index and reduce side effects. Companies like Glatt, Lonza, and Patheon have extensive patent families covering multiparticulate formulations, some overlapping with the scope of EP2269603.
Patent families closely related include:
- US Patent 7,947,415 (Controlled-release multiparticulate systems)
- EP Patent 1,751,134 (Polymer-coated beads)
- WO Patent 2016/085726 (Targeted delivery via pH-sensitive coatings)
EP2269603 distinguishes itself through its specific manufacturing protocols and formulation parameters, possibly providing a competitive advantage in ease of manufacturing and formulation flexibility.
Legal Status and Market Position
The patent, granted in 2011 and typically maintained for 20 years, is believed to be active, offering exclusivity in the European market. Its broad claims could serve as foundational IP in subsequent formulations or manufacturing process patents, shaping the landscape for patent applications in controlled-release pharmaceuticals.
Strategic Implications
For pharmaceutical innovators, EP2269603 presents an influential barrier and licensing opportunity, especially in products requiring controlled, site-specific drug release. Its scope’s breadth and depth make it a valuable asset for patent infringement defenses or licensing negotiations.
Companies innovating in similar domains should carefully analyze this patent to design around its claims, possibly through alternative formulations, different manufacturing methods, or molecular modifications to the API or carriers.
Key Challenges and Opportunities
- Challenges: Potential challenges arise from prior art and similar patents; inventors must validate the novelty and inventive step through detailed patent landscaping.
- Opportunities: Licensing or acquiring rights to this patent could accelerate development of new formulations; alternatively, designing around its claims could differentiate new products while avoiding infringement.
Conclusion and Key Takeaways
- Scope and Claims: EP2269603 offers broad but well-defined protection over multiparticulate controlled-release systems, emphasizing polymer composition, particle architecture, and manufacturing methods.
- Patent Landscape: It sits within a crowded field of multiparticulate and controlled-release technology, distinguished by specific formulation and process features.
- Strategic Value: This patent serves as a key intellectual property asset for companies in drug delivery, providing opportunities for licensing, collaboration, or strategic design-around.
- Regulatory and Commercial Impact: Holding or navigating around EP2269603 can significantly influence product development timelines, exclusivity, and competitive positioning.
Overall, EP2269603 exemplifies a comprehensive approach to protecting innovative drug delivery systems in Europe, shaping the future patent landscape of controlled-release pharmaceuticals.
FAQs
-
What is the primary innovation of EP2269603?
It encapsulates a multiparticulate drug delivery system with specific formulations and manufacturing processes designed to modulate drug release kinetics.
-
Does this patent cover all controlled-release formulations?
No. Its claims are focused on specific compositions and methods, but it broadly encompasses various multiparticulate systems within its scope.
-
Can a competitor develop a similar system without infringing this patent?
Possibly, by designing alternative formulations, utilizing different polymers, or employing different manufacturing techniques that do not fall within the patent claims.
-
How does EP2269603 compare to prior art?
It extends existing multiparticulate technologies by integrating particular polymer combinations and manufacturing methods, potentially providing an inventive step over prior art.
-
What is the strategic significance of this patent in the European pharmaceutical market?
Its broad scope provides a strong IP position for controlled-release drugs, enabling exclusivity, licensing opportunities, and market differentiation.
References
[1] European Patent EP2269603, Method of delivering therapeutic agents.
[2] Prior art references on controlled-release multiparticulates and polymer coating technologies (as discussed).
[3] Patent landscapes and filings from relevant pharmaceutical patent offices.
